IMUC — Eom Pharmaceutical Holdings Share Price
Last trade - 00:00- $19.13m
- $20.97m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1314.46% | ||
| Return on Equity | -960.21% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.
Directors
- Rahul Singhvi LED
- John Yu DRC (51)
- Gregg Lapointe IND (61)
- Mark Schlossberg IND (57)
- Gary Titus IND (59)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- March 20th, 1987
- Public Since
- September 19th, 2006
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 113,270,751
- Address
- 30721 Russell Ranch Road, Suite 140, WESTLAKE VILLAGE, 91362
- Web
- https://imuc.com/
- Phone
- +1 8182642300
- Auditors
- Marcum LLP
Upcoming Events for IMUC
Similar to IMUC
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 20:30 UTC, shares in Eom Pharmaceutical Holdings are trading at $0.19. This share price information is delayed by 15 minutes.
Shares in Eom Pharmaceutical Holdings last closed at $0.19 and the price had moved by -34.03% over the past 365 days. In terms of relative price strength the Eom Pharmaceutical Holdings share price has underperformed the S&P500 Index by -44.63% over the past year.
There is no consensus recommendation for this security.
Eom Pharmaceutical Holdings does not currently pay a dividend.
Eom Pharmaceutical Holdings does not currently pay a dividend.
Eom Pharmaceutical Holdings does not currently pay a dividend.
To buy shares in Eom Pharmaceutical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.19, shares in Eom Pharmaceutical Holdings had a market capitalisation of $21.52m.
Here are the trading details for Eom Pharmaceutical Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: IMUC
Based on an overall assessment of its quality, value and momentum Eom Pharmaceutical Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eom Pharmaceutical Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -4.97%.
As of the last closing price of $0.19, shares in Eom Pharmaceutical Holdings were trading -27.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eom Pharmaceutical Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eom Pharmaceutical Holdings' management team is headed by:
- Rahul Singhvi - LED
- John Yu - DRC
- Gregg Lapointe - IND
- Mark Schlossberg - IND
- Gary Titus - IND